Loading
NASDAQTechnologySoftware - Application
Latest quote
$1.21
−$0.01 · -0.82%
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.
Latest quote
$1.21
−$0.01 · -0.82%
After-hours
$1.23
+$0.02 · +1.65%
Oct 8, 5:19 PM ET
Regular session · ET · Market data may be delayed.
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.
Day range
Current $1.21
52-week range
Current $1.21
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
64
Undervalued
Sentiment
48
Mixed
Risk
67
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.
Day range
Current $1.21
52-week range
Current $1.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.14M USD | 108K USD | 498K USD | — | 32K USD |
| Cost of goods sold | 497K USD | 67K USD | — | — | — |
| Gross profit | 645K USD | 41K USD | 498K USD | — | 32K USD |
| Research and development | 1.48M USD | 1.95M USD | 741K USD | 1.27M USD | 2.93M USD |
| Selling, general, and administrative | 7.77M USD | 7.33M USD | 2.84M USD | 1.98M USD | 1.68M USD |
| Operating expenses | 9.25M USD | 9.22M USD | 3.58M USD | 3.33M USD | 4.69M USD |
| Interest income | 89K USD | — | — | — | — |
| Interest expense | 159K USD | 69K USD | 18K USD | 574K USD | 135K USD |
| Depreciation and amortization | 172K USD | 67K USD | — | 14K USD | 429K USD |
| Operating income | −8.61M USD | −9.18M USD | −3.08M USD | −3.33M USD | −4.65M USD |
| Net income | −19.88M USD | −10.46M USD | −2.6M USD | −3.79M USD | −4.38M USD |
Company facts updated Oct 8, 2026.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 18, 2023 | 1:10 | — | — |
Stock split | Apr 22, 1997 | 3:1 | — | — |
Stock split | Jan 31, 1997 | 3:1 | — | — |
Effective Oct 18, 2023
1:10
Effective Apr 22, 1997
3:1
Effective Jan 31, 1997
3:1
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
